Michael R. Chase
Michael R. Chase has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Sarah M. Fortune
Harvard University
6 shared publications - Forrest Hopkins
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA
3 shared publications - Philana Ling Lin
Children's Hospital of Pittsburgh
3 shared publications - Amy J. Myers
University of Pittsburgh School of Medicine 1 Department of Microbiology and Molecular Genetics Pittsburgh, PA
2 shared publications - Andrew W. Simonson
University of Pittsburgh School of Medicine 1 Department of Microbiology and Molecular Genetics Pittsburgh, PA
2 shared publications - Caylin Gwendolyn Maria Winchell
University of Pittsburgh School of Medicine 1 Department of Microbiology and Molecular Genetics Pittsburgh, PA
2 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by American Society for Microbiology in mSystems
- Vol. 11 (8)
Population-level genome sequencing reveals distinct Mycobacterium tuberculosis intrahost mutational trajectories in simian immunodeficiency virus-coinfected and antiretroviral treated non-human primates
Whole-genome sequencing of Mycobacterium tuberculosis (Mtb) populations from clinical samples has increasingly identified genes undergoing selection within and between hosts that drive differential infection and treatment outcomes. However, the intrahost Mtb mutational landscape—especially in the context of human immunodeficiency virus (HIV) coinfection and antiretroviral therapy (ART)—remains less clear, as do the potential impacts of such mutations on Mtb infection dynamics. Here, we performed whole-genome sequencing of Mtb populations isolated from 477 infected tissues across 20 non-human primates (NHP), including animals co-infected with simian immunodeficiency virus (SIV) with or without virological suppression by ART. We identified 116 mutations that emerged during infection, including those that are overrepresented within individual tissues and a subset that are shared across tissues during Mtb dissemination. We further find differential mutation trajectories across treatment groups, with higher mutation frequency and bacterial outgrowth in SIV-infected hosts and increased prevalence of oxidative damage-associated mutations in coinfected animals on ART. Finally, we demonstrate a common pattern of mutation in Mtb lipid metabolism and polyketide synthase genes and identify a subset of NHP-derived mutations that have also independently arisen in human clinical isolates. Together, our population-based sequencing uncovers Mtb diversification during early infection, captures discrete bacterial dissemination events, and infers differential immune pressures faced by Mtb in the setting of SIV-Mtb coinfection and ART suppression. IMPORTANCE: Tuberculosis (TB) remains a leading cause of death worldwide, especially in people living with HIV (PLHIV). How HIV infection and antiretroviral therapy impact Mycobacterium tuberculosis (Mtb) intrahost evolution remains unclear. Using whole-genome sequencing from hundreds of infected tissues from non-human primates, we find that simian immunodeficiency virus coinfected hosts and those receiving antiretroviral therapy exert different immune pressures on Mtb, leading to differences in mutation rates and types of DNA damage that are incurred. Mtb mutations were enriched in genes involved in lipid metabolism, and some of these are also seen in human TB strains. This work highlights the role of immune pressure in altering bacterial pathways that may enable Mtb adaptation to the host.
- 18 August 2026
- Published by American Society for Microbiology in mSystems
- Vol. 11 (8)
Open AccessPopulation-level genome sequencing reveals distinct Mycobacterium tuberculosis intrahost mutational trajectories in simian immunodeficiency virus-coinfected and antiretroviral treated non-human primates
Whole-genome sequencing of Mycobacterium tuberculosis (Mtb) populations from clinical samples has increasingly identified genes undergoing selection within and between hosts that drive differential infection and treatment outcomes. However, the intrahost Mtb mutational landscape—especially in the context of human immunodeficiency virus (HIV) coinfection and antiretroviral therapy (ART)—remains less clear, as do the potential impacts of such mutations on Mtb infection dynamics. Here, we performed whole-genome sequencing of Mtb populations isolated from 477 infected tissues across 20 non-human primates (NHP), including animals co-infected with simian immunodeficiency virus (SIV) with or without virological suppression by ART. We identified 116 mutations that emerged during infection, including those that are overrepresented within individual tissues and a subset that are shared across tissues during Mtb dissemination. We further find differential mutation trajectories across treatment groups, with higher mutation frequency and bacterial outgrowth in SIV-infected hosts and increased prevalence of oxidative damage-associated mutations in coinfected animals on ART. Finally, we demonstrate a common pattern of mutation in Mtb lipid metabolism and polyketide synthase genes and identify a subset of NHP-derived mutations that have also independently arisen in human clinical isolates. Together, our population-based sequencing uncovers Mtb diversification during early infection, captures discrete bacterial dissemination events, and infers differential immune pressures faced by Mtb in the setting of SIV-Mtb coinfection and ART suppression. IMPORTANCE: Tuberculosis (TB) remains a leading cause of death worldwide, especially in people living with HIV (PLHIV). How HIV infection and antiretroviral therapy impact Mycobacterium tuberculosis (Mtb) intrahost evolution remains unclear. Using whole-genome sequencing from hundreds of infected tissues from non-human primates, we find that simian immunodeficiency virus coinfected hosts and those receiving antiretroviral therapy exert different immune pressures on Mtb, leading to differences in mutation rates and types of DNA damage that are incurred. Mtb mutations were enriched in genes involved in lipid metabolism, and some of these are also seen in human TB strains. This work highlights the role of immune pressure in altering bacterial pathways that may enable Mtb adaptation to the host.
- Top Cited PapersOpen Access
- 6 February 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (4)
Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes
Tuberculosis (TB) is a major health burden worldwide despite widespread intradermal (ID) BCG vaccination in newborns. We previously demonstrated that changing the BCG route and dose from 5 × 105 CFUs ID to 5 × 107 CFUs i.v. resulted in prevention of Mycobacterium tuberculosis (Mtb) infection and TB disease in highly susceptible nonhuman primates. Identifying immune mechanisms protection following i.v. BCG will facilitate development of more effective vaccines against TB. Here, we depleted lymphocyte subsets prior to and during Mtb challenge in i.v. BCG–vaccinated macaques to identify those necessary for protection. Depletion of adaptive CD4 T cells, but not adaptive CD8αβ T cells, resulted in loss of protection with increased Mtb burdens and dissemination, indicating that CD4 T cells are critical to i.v. BCG–mediated protection. Depletion of unconventional CD8α-expressing lymphocytes (NK cells, innate T cells, and CD4+CD8α+ double-positive T cells) abrogated protection in most i.v. BCG–immunized macaques, supporting further investigation into which of these cell subsets contribute to protection after vaccination.
- 6 February 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (4)
Top Cited PapersOpen AccessIntravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes
Tuberculosis (TB) is a major health burden worldwide despite widespread intradermal (ID) BCG vaccination in newborns. We previously demonstrated that changing the BCG route and dose from 5 × 105 CFUs ID to 5 × 107 CFUs i.v. resulted in prevention of Mycobacterium tuberculosis (Mtb) infection and TB disease in highly susceptible nonhuman primates. Identifying immune mechanisms protection following i.v. BCG will facilitate development of more effective vaccines against TB. Here, we depleted lymphocyte subsets prior to and during Mtb challenge in i.v. BCG–vaccinated macaques to identify those necessary for protection. Depletion of adaptive CD4 T cells, but not adaptive CD8αβ T cells, resulted in loss of protection with increased Mtb burdens and dissemination, indicating that CD4 T cells are critical to i.v. BCG–mediated protection. Depletion of unconventional CD8α-expressing lymphocytes (NK cells, innate T cells, and CD4+CD8α+ double-positive T cells) abrogated protection in most i.v. BCG–immunized macaques, supporting further investigation into which of these cell subsets contribute to protection after vaccination.
- Top Cited PapersOpen Access
- 16 October 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (12)
CD8+ lymphocytes are critical for early control of tuberculosis in macaques
The functional role of CD8+ lymphocytes in tuberculosis remains poorly understood. We depleted innate and/or adaptive CD8+ lymphocytes in macaques and showed that loss of all CD8α+ cells (using anti-CD8α antibody) significantly impaired early control of Mycobacterium tuberculosis (Mtb) infection, leading to increased granulomas, lung inflammation, and bacterial burden. Analysis of barcoded Mtb from infected macaques demonstrated that depletion of all CD8+ lymphocytes allowed increased establishment of Mtb in lungs and dissemination within lungs and to lymph nodes, while depletion of only adaptive CD8+ T cells (with anti-CD8β antibody) worsened bacterial control in lymph nodes. Flow cytometry and single-cell RNA sequencing revealed polyfunctional cytotoxic CD8+ lymphocytes in control granulomas, while CD8-depleted animals were unexpectedly enriched in CD4 and γδ T cells adopting incomplete cytotoxic signatures. Ligand-receptor analyses identified IL-15 signaling in granulomas as a driver of cytotoxic T cells. These data support that CD8+ lymphocytes are required for early protection against Mtb and suggest polyfunctional cytotoxic responses as a vaccine target.
- 16 October 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (12)
Top Cited PapersOpen AccessCD8+ lymphocytes are critical for early control of tuberculosis in macaques
The functional role of CD8+ lymphocytes in tuberculosis remains poorly understood. We depleted innate and/or adaptive CD8+ lymphocytes in macaques and showed that loss of all CD8α+ cells (using anti-CD8α antibody) significantly impaired early control of Mycobacterium tuberculosis (Mtb) infection, leading to increased granulomas, lung inflammation, and bacterial burden. Analysis of barcoded Mtb from infected macaques demonstrated that depletion of all CD8+ lymphocytes allowed increased establishment of Mtb in lungs and dissemination within lungs and to lymph nodes, while depletion of only adaptive CD8+ T cells (with anti-CD8β antibody) worsened bacterial control in lymph nodes. Flow cytometry and single-cell RNA sequencing revealed polyfunctional cytotoxic CD8+ lymphocytes in control granulomas, while CD8-depleted animals were unexpectedly enriched in CD4 and γδ T cells adopting incomplete cytotoxic signatures. Ligand-receptor analyses identified IL-15 signaling in granulomas as a driver of cytotoxic T cells. These data support that CD8+ lymphocytes are required for early protection against Mtb and suggest polyfunctional cytotoxic responses as a vaccine target.
- Open Access
- 4 October 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (11) , 105312
Mycobacterial RNase E cleaves with a distinct sequence preference and controls the degradation rates of most Mycolicibacterium smegmatis mRNAs
- 4 October 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (11) , 105312
Open AccessMycobacterial RNase E cleaves with a distinct sequence preference and controls the degradation rates of most Mycolicibacterium smegmatis mRNAs
- Open Access
- 4 May 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (5) , eaao1478
Posttranslational modification of a histone-like protein regulates phenotypic resistance to isoniazid in mycobacteria
A bacterial histone-like protein regulates the formation of privileged, drug-tolerant subpopulations of mycobacteria.
- 4 May 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (5) , eaao1478
Open AccessPosttranslational modification of a histone-like protein regulates phenotypic resistance to isoniazid in mycobacteria
A bacterial histone-like protein regulates the formation of privileged, drug-tolerant subpopulations of mycobacteria.
- Open Access
- 5 March 2018
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 14 (3) , e1006939
TnSeq of Mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities
Once considered a phenotypically monomorphic bacterium, there is a growing body of work demonstrating heterogeneity among Mycobacterium tuberculosis (Mtb) strains in clinically relevant characteristics, including virulence and response to antibiotics. However, the genetic and molecular basis for most phenotypic differences among Mtb strains remains unknown. To investigate the basis of strain variation in Mtb, we performed genome-wide transposon mutagenesis coupled with next-generation sequencing (TnSeq) for a panel of Mtb clinical isolates and the reference strain H37Rv to compare genetic requirements for in vitro growth across these strains. We developed an analytic approach to identify quantitative differences in genetic requirements between these genetically diverse strains, which vary in genomic structure and gene content. Using this methodology, we found differences between strains in their requirements for genes involved in fundamental cellular processes, including redox homeostasis and central carbon metabolism. Among the genes with differential requirements were katG, which encodes the activator of the first-line antitubercular agent isoniazid, and glcB, which encodes malate synthase, the target of a novel small-molecule inhibitor. Differences among strains in their requirement for katG and glcB predicted differences in their response to these antimicrobial agents. Importantly, these strain-specific differences in antibiotic response could not be predicted by genetic variants identified through whole genome sequencing or by gene expression analysis. Our results provide novel insight into the basis of variation among Mtb strains and demonstrate that TnSeq is a scalable method to predict clinically important phenotypic differences among Mtb strains. Tuberculosis, caused by the bacterium Mycobacterium tuberculosis (Mtb), remains a serious global health problem, causing ~1.5 million deaths a year world-wide. Like other bacterial pathogens, diversity among strains of Mtb contributes to differences in infection outcomes, vaccine efficacy, and response to antibiotic treatment. Currently, the important genetic differences that contribute to variation among Mtb strains remain poorly understood. In this study, we applied a functional genomics technique called TnSeq to a panel of Mtb clinical strains to investigate the genetic basis of strain diversity. We identified a number of genes that are differentially required for growth in culture among these strains. Some of these genes are involved in the response to antibiotics, including the first-line antitubercular agent isoniazid and a novel antitubercular drug currently in development. We found that the genetic differences between strains uncovered by TnSeq predicted responses to these antibiotics. Our results demonstrate the utility of TnSeq for identifying clinically relevant differences among Mtb strains.
- 5 March 2018
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 14 (3) , e1006939
Open AccessTnSeq of Mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities
Once considered a phenotypically monomorphic bacterium, there is a growing body of work demonstrating heterogeneity among Mycobacterium tuberculosis (Mtb) strains in clinically relevant characteristics, including virulence and response to antibiotics. However, the genetic and molecular basis for most phenotypic differences among Mtb strains remains unknown. To investigate the basis of strain variation in Mtb, we performed genome-wide transposon mutagenesis coupled with next-generation sequencing (TnSeq) for a panel of Mtb clinical isolates and the reference strain H37Rv to compare genetic requirements for in vitro growth across these strains. We developed an analytic approach to identify quantitative differences in genetic requirements between these genetically diverse strains, which vary in genomic structure and gene content. Using this methodology, we found differences between strains in their requirements for genes involved in fundamental cellular processes, including redox homeostasis and central carbon metabolism. Among the genes with differential requirements were katG, which encodes the activator of the first-line antitubercular agent isoniazid, and glcB, which encodes malate synthase, the target of a novel small-molecule inhibitor. Differences among strains in their requirement for katG and glcB predicted differences in their response to these antimicrobial agents. Importantly, these strain-specific differences in antibiotic response could not be predicted by genetic variants identified through whole genome sequencing or by gene expression analysis. Our results provide novel insight into the basis of variation among Mtb strains and demonstrate that TnSeq is a scalable method to predict clinically important phenotypic differences among Mtb strains. Tuberculosis, caused by the bacterium Mycobacterium tuberculosis (Mtb), remains a serious global health problem, causing ~1.5 million deaths a year world-wide. Like other bacterial pathogens, diversity among strains of Mtb contributes to differences in infection outcomes, vaccine efficacy, and response to antibiotic treatment. Currently, the important genetic differences that contribute to variation among Mtb strains remain poorly understood. In this study, we applied a functional genomics technique called TnSeq to a panel of Mtb clinical strains to investigate the genetic basis of strain diversity. We identified a number of genes that are differentially required for growth in culture among these strains. Some of these genes are involved in the response to antibiotics, including the first-line antitubercular agent isoniazid and a novel antitubercular drug currently in development. We found that the genetic differences between strains uncovered by TnSeq predicted responses to these antibiotics. Our results demonstrate the utility of TnSeq for identifying clinically relevant differences among Mtb strains.